We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Poised for Growth Despite Regulatory Hurdles
Read MoreHide Full Article
On Nov 7, we updated our research report on CIGNA Corp. (CI - Free Report) . The company’s third-quarter 2016 consolidated revenue increased 5% year over year to $9.9 billion. It reported adjusted income from operations of $503 million or $1.94 per share, reflecting strong performance in its Commercial Health Care and Global Supplemental Benefits business lines and improving results in its Group Disability and Life segment.
The company is consistently making investments in value-based care programs and incentive payment models to provide quality care at affordable cost. It tries to achieve this via collaborative accountable care (CAC) arrangements. It has 160 such arrangements in place across 29 states, serving over two million customers. Its CAC initiatives have also helped in controlling medical cost.
Also, the company’s Global Health Care and Global Supplemental Benefits businesses are performing strongly with high customer retention levels and solid revenue and earnings growth.
Cigna has been growing it membership for the past many quarters. The company ended the third quarter with more than 15.2 million medical members, up 2.2% year over year. We expect a rise in membership going forward, driven by organic growth in Cigna’s Middle Market, International, Select, and Medicare segments. For 2016, the company expects global medical membership to increase in the low single-digit percentage range.
Nevertheless, the company faces a ban on selling private Medicare plans this enrollment season because of an investigation by U.S. regulators. The ban was imposed because the company was found guilty of non compliance with rules relating to Medicare policies.
The company has also been sued by the Justice Department over its acquisition by Anthem Inc. .
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cigna (CI) Poised for Growth Despite Regulatory Hurdles
On Nov 7, we updated our research report on CIGNA Corp. (CI - Free Report) . The company’s third-quarter 2016 consolidated revenue increased 5% year over year to $9.9 billion. It reported adjusted income from operations of $503 million or $1.94 per share, reflecting strong performance in its Commercial Health Care and Global Supplemental Benefits business lines and improving results in its Group Disability and Life segment.
The company is consistently making investments in value-based care programs and incentive payment models to provide quality care at affordable cost. It tries to achieve this via collaborative accountable care (CAC) arrangements. It has 160 such arrangements in place across 29 states, serving over two million customers. Its CAC initiatives have also helped in controlling medical cost.
Also, the company’s Global Health Care and Global Supplemental Benefits businesses are performing strongly with high customer retention levels and solid revenue and earnings growth.
Cigna has been growing it membership for the past many quarters. The company ended the third quarter with more than 15.2 million medical members, up 2.2% year over year. We expect a rise in membership going forward, driven by organic growth in Cigna’s Middle Market, International, Select, and Medicare segments. For 2016, the company expects global medical membership to increase in the low single-digit percentage range.
CIGNA CORP Price and Consensus
CIGNA CORP Price and Consensus | CIGNA CORP Quote
Nevertheless, the company faces a ban on selling private Medicare plans this enrollment season because of an investigation by U.S. regulators. The ban was imposed because the company was found guilty of non compliance with rules relating to Medicare policies.
The company has also been sued by the Justice Department over its acquisition by Anthem Inc. .
Cigna carries a Zacks Rank #3 (Hold). Other health insurers that have reported better-than-expected third-quarter earnings like Cigna include UnitedHealth Group Inc. (UNH - Free Report) and Humana Inc. (HUM - Free Report) both with a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>